Glioma cell activation by Alzheimer's peptide Aβ1-42, α1-antichymotrypsin, and their mixture

Cellular and Molecular Life Sciences

Volumn 59, Issue 10, 2002, Pages 1734-1743

  Sun, Y X ^a   Wright, H T ^b   Janciauskiene, S ^a  

^a UMAS   (Sweden)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Alzheimer's peptide A 1 42; Cytokine; Inflammation; Lipid metabolism; antichymotrypsin

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; GLIOMA CELL; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID STORAGE; MOLECULAR INTERACTION; PROTEIN TRANSPORT;

EID: 0036809846     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012501     Document Type: Article

References (70)

1. Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120: 885-890
2. Verbeek M. M., Ruiter D. J. and Waal R. M. de (1997) The role of amyloid in the pathogenesis of Alzheimer's disease. Biol. Chem. 378: 937-950
3. Kawahara M. and Kuroda Y. (2000) Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: Channel formation and disruption of calcium homeostasis. Brain Res. Bull. 53: 389-397
4. Hensley K., Carney J. M., Mattson M. P., Aksenova M., Harris M., Wu J. F. et al. (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 91: 3270-3274
5. Koo E. H., Park L. and Selkoe D. J. (1993) Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc. Natl. Acad. Sci. USA 90: 4748-4752
6. Lorenzo A. and Yankner B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 91: 12243-12247
7. Irizarry M. C., Soriano F., McNamara M., Page K. J., Schenk D., Games D. et al. (1997) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17: 7053-7059
8. Martin L. J., Pardo C. A., Cork L. C. and Price D. L. (1994) Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am. J. Pathol. 145: 1358-1381
9. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M. et al. (1998) Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95: 6448-6453
10. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M. et al. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19: 8876-8884
11. Zhu Y. J., Lin H. and Lal R. (2000) Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: Evidence for AbetaP-channel-mediated cellular toxicity. FASEB J. 14: 1244-1254
12. Bohrmann B., Tjernberg L., Kuner P., Poli S., Levet-Trafit B., Naslund J. et al. (1999) Endogenous proteins controlling amyloid beta-peptide polymerization: Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J. Biol. Chem. 274: 15990-15995
13. Michikawa M., Gong J. S., Fan Q., W. Sawamura N. and Yanagisawa K. (2001) A novel action of Alzheimer's amyloid beta-protein (Abeta): Oligomeric Abeta promotes lipid release. J. Neurosci. 21: 7226-7235
14. Wehr H., Parnowski T., Puzynski S., Bednarska-Makaruk M., Bisko M, Kotapka-Minc S. et al. (2000) Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement. Geriatr. Cogn. Disord. 11: 70-73
15. Merched A., Xia Y., Visvikis S., Serot J. M. and Siest G. (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein A1 concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 21: 27-30
16. Kuo Y. M., Emmerling M. R., Bisgaier C. L., Essenburg A. D., Lampert H. C., Drumm D. et al. (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Abeta 1-42 levels. Biochem. Biophys. Res. Commun. 252: 711-715
17. Rodrigues C. M, Sola S., Brito M. A., Brondino C. D., Brites D. and Moura J. J. (2001) Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: Protective role of tauroursodeoxycholate. Biochem Biophys. Res. Commun. 281: 468-474
18. Strosznajder J. B., Zambrzycka A., Kacprzak M. D. and Strosznajder R. P. (1999) Amyloid beta peptide 25-35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. J. Mol. Neurosci. 12: 101-109
19. Yip C. M., Elton E. A., Darabie A. A., Morrison M. R. and McLaurin J. (2001) Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J. Mol. Biol. 311: 723-734
20. Howland D. S., Trusko S. P., Savage M. J., Reaume A. G., Lang D. M., Hirsch J. D. et al. (1998) Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. 273:16576-16582
21. Janciauskiene S., Wright H. T. and Lindgren S. (1999) Fibrillar Alzheimer's amyloid peptide Abeta(1-42) stimulates low density lipoprotein binding and cell association, free radical production and cell cytotoxicity in PC12 cells. Neuropept. Res. 33: 510-516
22. Lue L. F., Walker D. G. and Rogers J. (2001) Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol. Aging 22: 945-956
23. Deb S. and Gottschall P. E. (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J. Neurochem. 66: 1641-1647
24. Del Bo R., Angeretti N., Lucca E., De Simoni M. G. and Forloni G. (1995) Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neurosci. Lett. 188: 70-74
25. Styren S. D., Kamboh M. I. and DeKosky, S.T. (1998) Expression of differential immune factors in temporal cortex and cerebellum: The role of alpha-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. J. Comp. Neurol. 396: 511-520
26. Hamazaki H. (1995) Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer's beta-amyloid peptide. J. Biol. Chem. 270: 10392-10394
27. Veerhuis R., Janssen I., De Groot C. J., Van Muiswinkel F. L., Hack C. E. and Eikelenboom P. (1999) Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp. Neurol. 160: 289-299
28. Asahina M., Yoshiyama Y. and Hattori T. (2001) Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 20: 60-63
29. Oda T., Wals P., Osterburg H. H., Johnson S. A., Pasinetti G. M., Morgan T. E. et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136: 22-31
30. Abraham C. R. and Potter H. (1989) The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease. Ann. Med. 21: 77-81
31. Rozemuller J. M., Abbink J. J., Kamp A. M., Stam F. C., Hack C. E. and Eikelenboom P. (1991) Distribution pattern and functional state of alpha 1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease: A immunohistochemical study with monoclonal antibodies against native and inactivated alpha 1-antichymotrypsin. Acta Neuropathol. (Berl) 82: 200-207
32. McLaurin J., Yang D., Yip C. M. and Fraser P. E. (2000) Modulating factors in amyloid-beta fibril formation. J. Struct. Biol. 130: 259-270
33. Eriksson S., Janciauskiene S. and Lannfelt L. (1995) Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA 92: 2313-2317
34. Janciauskiene S., Rubin H., Lukacs C. M. and Wright H. T. (1998) Alzheimer's peptide Abeta1-42 binds to two beta-sheets of alphal-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 273: 28360-28364
35. Fraser P. E., Nguyen J. T., McLachlan D. R., Abraham C. R. and Kirschner D. A. (1993) Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 61: 298-305
36. Yamin R, Malgeri E. G., Sloane J. A., McGraw W. T. and Abraham C. R. (1999) Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation. J. Biol. Chem. 274: 18777-18784
37. Sun Y. X., Wright H. T. and Janciauskiene S. (2002) Alphal-antichymotrypsin/Alzheimer's peptide Abeta (1-42) complex perturbs lipid metabolism and activates transcription factors PPARgamma and NFkappaB in human neuroblastoma (Kelly) cells. J. Neurosci. Res. 67: 511-522
38. McGeer P. L. and McGeer E. G. (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22: 799-809
39. Kajkowski E. M., Lo C. F., Ning X., Walker S., Sofia H. J., Wang W. et al. (2001) Beta-amyloid peptide-induced apoptosis regulated by a novel protein containing a G protein activation module. J. Biol. Chem. 276: 18748-18756
40. Ishii K., Muelhauser F., Liebl U., Picard M., Kuhl S., Penke B. et al. (2000) Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: Reversal by inhibition of the inducible NO synthase. FASEB J. 14: 1485-1489
41. Riemenschneider M., Schmolke M., Lautenschlager N., Guder W. G., Vanderstichele H., Vanmechelen E. et al. (2000) Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284: 85-88
42. Kontush A., Berndt C., Weber W., Akopyan V., Arlt S., Schippling S. et al. (2001) Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30: 119-128
43. Tsuda M., Ohkubo T., Kamiguchi H., Suzuki K., Nakasaki H., Mitomi T. et al. (1982) Purification, properties and identification of a serum DNA binding protein (64DP) and its microheterogeneity. J. Exp. Chin. Med. 7: 201-211
44. Janciauskiene S. and Eriksson S. (1993) In vitro complex formation between cholesterol and alpha 1-proteinase inhibitor. FEBS Lett. 316: 269-272
45. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurements with folin phenol reagents. J. Biol. Chem. 193: 265-275
46. Shepherd J., Bedford D. K. and Morgan H. G. (1976) Radioiodination of human low density lipoprotein: A comparison of four methods. Clin. Chim. Acta. 66: 97-109
47. Weber C., Draude G., Weber K. S., Wubert J., Lorenz R. L. and Weber P.C. (1999) Downregulation by tumor necrosis factor-alpha of monocyte CCR2 expression and monocyte chemotactic protein-1-induced transendothelial migration is antagonized by oxidized low-density lipoprotein: A potential mechanism of monocyte retention in atherosclerotic lesions. Atherosclerosis 145: 115-123
48. Chomczynski P., and Sacchi N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159
49. Janciauskiene S., Wright H. T. and Lindgren, S. (1999) Atherogenic properties of human monocytes induced by the carboxyl terminal proteolytic fragment of alpha-1-antitrypsin. Atherosclerosis 147: 263-275
50. Shah S. N. and Johnson R. C. (1988) Effect of serum lipoproteins on growth and sterol synthesis in cultured rat brain glial cells. J. Neurochem. 50: 1529-1536
51. Moraga F. and Janciauskiene S. (2000) Activation of primary human monocytes by the oxidized form of alphal-antitrypsin. J. Biol. Chem. 275: 7693-7700
52. Tanaka T., Tatsuno I., Noguchi Y., Uchida D., Oeda T., Narumiya S. et al. (1998) Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes: Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression. J. Biol. Chem. 273: 26772-26778
53. Howard B. V., Howard W. J., De la Llera M. and Kefalides N. A (1976) Triglyceride accumulation in cultured human fibroblasts: The effects of hypertriglyceridemic serum. Atherosclerosis 23: 521-534
54. Siperstein M. D. (1984) Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J. Lipid Res. 25: 1462-1468
55. Gebhardt A. and Niendorf A. (1995) Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines. J. Cancer Res. Clin. Oncol. 121: 343-349
56. Meda L., Baron P. and Scarlato G. (2001) Glial activation in Alzheimer's disease: The role of Abeta and its associated proteins. Neurobiol. Aging 22: 885-893
57. Johnstone M., Gearing A. J. and Miller K. M. (1999) A central role for astrocytes in the inflammatory response to beta-amyloid: Chemokines, cytokines and reactive oxygen species are produced. J. Neuroimmunol. 93: 182-193
58. Abraham C. R. (1992) The role of the acute-phase protein alpha 1-antichymotrypsin in brain dysfunction and injury. Res. Immunol. 143: 631-636
59. Kordula T., Bugno M., Rydel R. E. and Travis J. (2000) Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes. J. Neurosci. 20: 7510-7516
60. Kordula T., Rydel R. E., Brigham E. F., Horn F., Heinrich P. C. and Travis J. (1998) Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alphal-antichymotrypsin expression in human cortical astrocytes. J. Biol. Chem. 273: 4112-4118
61. Ferrer-Lopez P., Renesto P., Schattner M., Bassot S., Laurent P. and Chignard M. (1990) Activation of human platelets by C5a-stimulated neutrophils: A role for cathepsin G. Am. J. Physiol. 258: C1100-1107
62. Bianca V. D., Dusi S., Bianchini E., Dal Pra I. and Rossi F. (1999) Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils: A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J. Biol. Chem. 274: 15493-15499
63. Kang J., Park E. J., Jou I., Kim J. H. and Joe E. H. (2001) Reactive oxygen species mediate A beta(25-35)-induced activation of BV-2 microglia. Neuroreport 12: 1449-1452
64. Frears E. R., Stephens D. J., Walters C. E., Davies H. and Austen B. M. (1999) The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10: 1699-1705
65. Galbete J. L., Martin T. R., Peressini E., Modena P., Bianchi R. and Forloni G. (2000) Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem. J. 348: 307-313
66. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. and Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95: 6460-6464
67. Koudinov A. R., Koudinova N. V. and Berezov T. T. (1996) Alzheimer's peptides A beta 1-40 and A beta 1-28 inhibit the plasma cholesterol esterification rate. Biochem. Mol. Biol. Int. 38: 747-752
68. Osborne T. F. and LaMorte V. J. (1998) Molecular aspects in feedback regulation of gene expression by cholesterol in mammalian cells. Methods 16: 42-48
69. Liu Y., Peterson D. A. and Schubert D. (1998) Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl. Acad. Sci. USA 95: 13266-13271
70. Ruan X. Z., Varghese Z., Powis S. H. and Moorhead J. F. (2001) Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation. Kidney Int. 60: 1716-1725